Estée Lauder Signs Acclaimed Model Imaan Hammam as New Global Brand Ambassador
1.5.2023 17:00:00 EEST | Business Wire | Press release
Estée Lauder announces one of fashion’s biggest stars, Dutch supermodel Imaan Hammam, as its newest Global Brand Ambassador. Imaan joins the current roster of Estée Lauder global talent including Adut Akech, Ana de Armas, Amanda Gorman, Bianca Brandolini D’Adda, Carolyn Murphy, Grace Elizabeth, Karlie Kloss, Kōki, and Yang Mi. Imaan’s first campaign debuts in July 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230501005396/en/
Estée Lauder Signs Acclaimed Model Imaan Hammam as New Global Brand Ambassador (Photo: Business Wire)
“Imaan has quickly become an icon in the fashion industry,” said Justin Boxford, Global Brand President, Estée Lauder and AERIN Beauty. “Aside from her phenomenal energy, charisma, beauty and drive, it’s her passion and dedication to advocating for young women everywhere that deeply connects to our brand’s core values and will help us continue to inspire our consumers globally.”
“I am so honored to be part of the Estée Lauder family,” said Imaan. “Estée Lauder has such a rich heritage and some of the most iconic beauty products, but I am most proud to be part of a brand that champions women’s advancement around the world.”
About Imaan Hammam:
Dutch Supermodel and activist Imaan Hammam is both a fashion industry icon and a shining example for young women everywhere. Of Moroccan and Egyptian descent, Imaan grew up in Amsterdam as one of the six children of two immigrants. Imaan made her runway debut in 2013 for Jean-Paul Gaultier, Givenchy, Hermes, Proenza Schouler, Chanel, and Valentino.
She is a favorite subject of acclaimed fashion photographers Steven Meisel, Craig McDean, Annie Leibovitz, David Sims, Mert & Marcus, Willy Vanderperre, Jamie Hawkesworth, Inez & Vinoodh, and Mario Sorrenti. She has covered the September issue of American Vogue as well as the Italian, British, French, Mexican, Arabic, Chinese, Spanish, and Japanese editions in addition to Harper’s Bazaar, WSJ, i-D, Elle, and Vanity Fair. She has also starred in campaigns for brands such as Tiffany & Co, Chanel, Versace, Fendi, Moschino, and Calvin Klein, among others.
As a global ambassador for non-profit She’s the First, also being named their 2021 ‘Powerhouse of the Year,’ Imaan advocates for young women from all backgrounds. Recognized for her role as an activist as well as for her contributions to the fashion industry, Imaan was awarded one of Bazaar’s Woman of the Year awards in 2020.
About Estée Lauder:
Estée Lauder is the flagship brand of The Estée Lauder Companies Inc. Founded by Estée Lauder, one of the world’s first female entrepreneurs, the brand today continues her legacy of creating the most innovative, sophisticated, high-performance skincare and makeup products and iconic fragrances – all infused with a deep understanding of women’s needs and desires. Today, Estée Lauder engages with women in over 150 countries and territories around the world and at dozens of touch points – from in-store to digital. And each of these relationships consistently reflects Estée’s powerful and authentic woman-to-woman point of view.
Follow @esteelauder on Instagram, Facebook, Twitter, YouTube and TikTok.
Follow @imaanhammam on Instagram and TikTok.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230501005396/en/
Contact information
Tara Connaughton
tconnaugh@estee.com
Katie Gunn
kagunn@estee-lauder.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom